Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Status Approved for marketing

Clinical Trial Summary

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

Clinical Trial Description

This is a study to collect information on adverse events (side effects) that occur during treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (CRPC). To participate in this study patients must have failed 1 or 2 chemotherapy regimens (1 of which contained a taxane such as docetaxel), reside in an area where abiraterone acetate is not yet available through local healthcare providers, and not be eligible for enrollment in any other ongoing clinical research study of abiraterone acetate. CRPC is progressive form of prostate cancer where the cancer cells become resistant to hormonal therapies that are designed to block the release or uptake of testosterone and the cancer cells metastasize (ie, spread to other parts of the body). Abiraterone acetate (referred to as abiraterone) is a drug currently under development for use in treating men with CRPC. Patients will be treated with abiraterone and prednisone daily until progression of clinical disease (ie, includes signs of clinical disease progression and/or clinical disease progression confirmed by radiographic and prostate-specific antigen [PSA] test results). Other reasons for discontinuation of treatment may include adverse events reported, initiation of other anticancer therapies, or the patient's inability to comply with dosing instructions. Patients will be followed for 30 days after the discontinuation of treatment with abiraterone acetate. Patients will take four 250-mg tablets of abiraterone orally at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day. Patients will also take 5 mg of oral prednisone, twice daily. Each treatment cycle consists of 28 days and patients will take abiraterone continually on a daily basis until disease progression is observed at which time abiraterone will be discontinued and the dose of prednisone reduced if clinically indicated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01217697
Study type	Expanded Access
Source	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status	Approved for marketing
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00377520` - A Trial for Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT04462926` - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed	N/A
Active, not recruiting	`NCT03344757` - Health Gatherings - For Your Health After Cancer	N/A
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Completed	`NCT03562897` - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer	Phase 2
Recruiting	`NCT04923178` - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Terminated	`NCT02543645` - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer	Phase 1
Terminated	`NCT04221828` - Trial of NanoPac Focal Therapy for Prostate Cancer	Phase 2
Not yet recruiting	`NCT05030077` - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma	Phase 2
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Completed	`NCT01523652` - Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients	N/A
Completed	`NCT04679675` - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial	N/A
Terminated	`NCT02386111` - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma	Phase 1
Completed	`NCT03081858` - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT04644432` - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma	Phase 2
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Completed	`NCT04435964` - Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment
Recruiting	`NCT04922047` - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)	Phase 1/Phase 2
Terminated	`NCT01918605` - Protection of Rectum From High Radiation Doses Using a Spacer	N/A
Completed	`NCT01316458` - Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy	Phase 2